Ordinary Submission – PACTRIMS 2017


Poster Number Abstract Title Author Country
P-1 The Absence of Epidemiology Data of Multiple Sclerosis in the Pacific, South Asia, South East Asia, and East Asian Regions Wing Loong Cheong Malaysia
P-2 The Steady Rise of Multiple Sclerosis in Sri Lanka: The Largest Series of Patients to Date Shanindra De Alwis Sri Lanka
P-3 Seasonality for the Occurrence of Central Nervous System Demyelinating Diseases In Soo Joo Republic of Korea
P-4 The Association between Sodium Intake and Multiple Sclerosis in Isfahan Population Sarah Ghorbani Iran
P-5 The Effect of Exclusive Breastfeeding on Postpartum Multiple Sclerosis Relapses Navideh Sahebi Vaighan Iran
P-6 Mortality in Multiple Sclerosis Murat Terzi Turkey
P-7 Inıtıal and Fınal Dıagnosıs: Multıple Sclerosıs Versus Mımıcs F. Belgin Balcı Turkey
P-8 Establishment of a Multidisciplinary Neuroimmunology Clinic Improves Care of Multiple Sclerosis Patients  Xue Juan Peng Singapore
P-9 Clinical Characteristics of The First Manifestation in Multiple Sclerosis  Yuge Wang China
P-10 Differences Between Patients with Multiple Sclerosis and Healthy Individuals in Terms of Falls, Balance, Mobility and Hand Functions Muhtesem Gedizlioglu Turkey
P-11 Olfactory Dysfunction in Multiple Sclerosis Ufuk Emre Turkey
P-12 Peripheral Neuropathy in Multiple Sclerosis: a Clinical and Electroneurophysiological Study Qin Bing China
P-13 The Investigation of Relationship between Core Stability and Trunk Position Sense with Disability Level in Multiple Sclerosis Patients Taskin Ozkan Turkey
P-14 The Effects of Core Endurance and Trunk Position Sense on Balance in Patients with Multiple Sclerosis Taskin Ozkan Turkey
P-15 Validity and Reliability of The Fatigue Severity Scale in A Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Population in Singapore  Suet Kuen Wong Singapore
P-16 Description of Quality of Sleep and Sleep Disorder Among Indonesian Multiple Sclerosis Foundation Members Gilang Saputra Indonesia
P-17 Always Alone with my MS Serpil Demirci Turkey
P-18 Varıables That Affect Lıfe Satısfactıon Of Multıple Sclerosıs Patıents  A Comparatıve Study Murat Terzi Turkey
P-19 The Role of Coping Styles in the Relationship between Personality Traits and Quality of Life of Multiple Sclerosis Patients Ehsan Sharifipour Iran
P-20 The Role of Diffusion Weighted Imaging in Demonstrating Acute Demyelinating Lesions Aysun Soysal Turkey
P-21 Differential Associations of Spinal Cord Atrophy with Clinical Disability between Japanese Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Yuri Nakamura Japan
P-22 Differentiation of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Using Deep Learning on Brain MRI Ju-Hong Min Republic of Korea
P-23 Contribution of Cortical Lesions to Cognitive Dysfunction in Japanese Patients with Multiple Sclerosis Shinoda Koji Japan
P-24 Brain Volume Loss Is Present in Japanese Patients with Multiple Sclerosis with No Evidence of Disease Activity Hiroaki Yokote Japan
P-25 Correlation Between Brain Volume Loss and Long-term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI Data  Till Sprenger Germany
P-26 EEG Changes in Patıents wıth Multıple Sclerosıs Who were Used Famprıdıne Gulnihal Kutlu Turkey
P-27 Visual Evoked Potential Abnormalities in Indonesian Multiple Sclerosis and Neuromyelitis Optic Spectrum Disorder Patients Adisresti Diwyacitta Indonesia
P-28 Deviated Repertoire of gd T Cells is Associated with Disease Severity of Multiple Sclerosis Maimaitijiang Guzailiayi Japan
P-29 Serum CCL20 and Its Association with SIRT1 Activity in Multiple Sclerosis Patients Li Rui China
P-30 Gut Microflora: Association between Appendectomy and Multiple Sclerosis and Neuromyelitis Optica Hean Sun Ooi Malaysia
P-31 Elevated Serum Levels of Sirtuin 1 in Multiple Sclerosis During Remission Ceyla Irkec Turkey
P-32 Effects of Therapy on The Serum Levels of Apelin and Sirtuin 1 İn Responder and Non- Responder Multiple Sclerosis Patients Ceyla Irkec Turkey
P-33 Adiponectin in Multiple Sclerosis and Neuro-Behçet’s Disease Ceyla Irkec Turkey
P-34 Dynamic Expression of Circulating MicroRNA-155 in Plasma of Patients with Multiple Sclerosis Qin Bing China
P-35 The Role of Melatonin in Control of Symptoms of Patients with Multiple Sclerosis Fardin Faraji Iran
P-36 Serum Homocysteine Levels and Cognitive Dysfunction in Multiple Sclerosis Patients Musa Kazim Onar Turkey
P-37 Evaluation of Thyroid Functions in Multiple Sclerosis: Preliminary Study Ufuk Emre Turkey
P-38 Effect of Apolipoprotein E Genotypes in Prognosis of Patients with Multiple Sclerosis Yusuf Tamam Turkey
P-39 Improvements and Success in the Management of Multiple Sclerosis: Fifteen years of Experience from a Single-centre Public Hospital  Lavanya Vijayasingham Malaysia
P-40 Access to Disease-modifying Treatment in Malaysia: A Multi-level and Multi-Actor Perspective Lavanya Vijayasingham Malaysia
P-41 Comparative Effectiveness Among the First-line Disease Modifying Therapies Multiple Sclerosis Relapse – a Nationwide Observational Study in Taiwan Chih-Ho Chou Taiwan
P-42 Is the New Brand-Generic of Glatiramer Acetate (Copamer®) 40 Mg Safe and Effective in Iranian Patients with RRMS? Roya Abolfazli Iran
P-43 Is There any Relationship between The Sexual Dysfunction and Immunomodulatory Therapy in Patients with Multiple Sclerosis? F. Belgin Balcı Turkey
P-44 Longitudinal Variations of Neuro Metabolites and MS Fatigue in Patients Treated with Dimethyl Fumarate Jameen ARM Australia
P-45 Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 Years in Patients with Relapsing-Remitting Multiple Sclerosis Reinhard Hohlfeld Germany
P-46 Fingolimod Significantly Lowers Neurofilament Light Chain Blood Levels in Relapsing-Remitting Multiple Sclerosis Patients as Compared with Interferon
Beta-1a or Placebo
Jens Kuhle Switzerland
P-47 Efficacy and Safety of Fingolimod for Multiple Sclerosis in Singapore Amy May Lin Quek Singapore
P-48 Running the HIT: Feasibility of Home Infusions of Tysabri™ For People with Multiple Sclerosis Tim Schultz Australia
P-49 A Pilot Time and Motion Study for Treatments of Relapsing Remitting Multiple Sclerosis (RRMS) in Australia Jeannette Lechner-Scott Australia
P-50 Analysis of Relapse Rates and Relapse-Free Patients in the CLARITY and CLARITY Extension Studies  Dominic Jack United Kingdom
P-51 Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study John King Australia
P-52 Cladribine Tablets for Treatment of Patients with Multiple Sclerosis (MS): Integrated Analysis of Safety from the MS Clinical Development Programme Stuart Cook United States
P-53 Long-Term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets (CT) Per Soelberg-Sorensen Denmark
P-54 Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells by Cladribine Tablets in Patients with Early and Relapsing MS Olaf Stuve United States
P-55 An Analysis of the Effects of Cladribine Tablets on Lymphocyte Surface Markers: CD4+ T Cell Subsets in the ORACLE-MS Study Olaf Stuve United States
P-56 Efficacy and Safety of Alemtuzumab in Korean Patients with Multiple Sclerosis: 1-Year Preliminary Results Hyun-June Shin Republic of Korea
P-57 Tolerability of Alemtuzumab in SPMS: Experience from one center  Jong-Mi Lee United States
P-58 Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) Simon Broadley Australia
P-59 Efficacy of a Third Course of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Experienced Disease Activity After the Initial Two Courses: Pooled Analysis of CARE-MS I and II Ho Jin Kim Republic of Korea
P-60 Durable Suppression of MRI Disease Activity and Reduction in Brain Volume Loss with Alemtuzumab in Patients with Active RRMS: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) Michael Barnett Australia
P-61 Durable Clinical Outcomes with Alemtuzumab in Patients with Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) Ho Jin Kim Republic of Korea
P-62 Restoration of Regulatory B Cell Deficiency Following Alemtuzumab Therapy in Patients with Active Multiple Sclerosis Yeseul Kim Republic of Korea
P-63 Patient-Reported Satisfaction With Teriflunomide Treatment In Patients With RRMS In Australian Clinical Practice: Aubpro Study Design Steve Vucic Australia
P-64 The Retrospectıve Evaluatıon of Effectıveness of Terıflunomıde Treatments in Multıple Sclerosıs Patıents Ömer Faruk Turan Turkey
P-65 A Subgroup Analysis of the Phase 3 TOWER Study Assessing Efficacy and Safety of Teriflunomide in Asian Patients with Relapsing Forms of MS Richard Macdonell Australia
P-66 Narrowband UVB Phototherapy for Clinically Isolated Syndrome: Delivering the Benefits of All UVB-Induced Molecules Marzena Fabis-Pedrini Australia
P-67 Preliminary Results of An Observational Study to Evaluate Integrative Medicine in Managing Fatigue and Cognitive Deficits Associated with Multiple Sclerosis  Alexander Yuk Lun Lau China
P-68 Neuromyelitis Optica: An 18-case Experience at Ho Chi Minh City University Medical Center in Vietnam Thi Vu Thuy Vietnam
P-69 Clinical Characteristics Analysis of Neuromyelitis Optica Spectrum Disorders Manifesting Brainstem Involvement as Initial Symptoms Wang Yanqiang China
P-70 Ethnic Differences in Clinical Manifestation of Neuromyelitis Optica Spectrum Disorder Su-Hyun Kim Republic of Korea
P-71 Nationwide Epidemiological Study of Neuromyelitis Optica in Japan Katsuichi Miyamoto Japan
P-72 Antibody Serology Can Influence Clinical Presentations in Neuromyelitis Optica Spectrum Disorder Yoon Byeol-A Republic of Korea
P-73 Characteristics of Patients Double-Seropositive of Antiphopholipid Antibody and Aquaporin4-Antibody Ju-Hong Min Republic of Korea
P-74 Low Prevalence of Anti Aquaporin 4 Antibody in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Western Australia Marzena Pedrini Australia
P-75 Discrimination of Spinal Cord Sarcoidosis from Neuromyelitis Optica Spectrum Disorer or Spondylotic Myelopathy Hiroshi Kuroda Japan
P-76 Differences in The Clinical and Laboratory Features According to The Lesion Length in Non-infectious Myelitis Sa-Yoon Kang Republic of Korea
P-77 Different Features between Pediatric-Onset and Adult-Onset Patients Who Are Seropositive For MOG-IgG: A Multicenter Study in South China Lu Chen China
P-78 Overlapping MOG Antibody Disease or NMOSD and Anti-NMDA Receptor Encephalitis: A Clinical Series and Systematic Review of the Literature Siyuan Fan China
P-79 Neuromyelitis optica spectrum disorders with Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein antibodies in Turkish Population:A Comparative Study Egemen Idiman Turkey
P-80 Differential Patterns of Demyelination and Remyelination Revealed by q-Space Myelin Map Imaging in NMOSD and MS Kenji Kufukihara Japan
P-81 Choroid Plexitis in Neuromyelitis Optica Spectrum Disorder  YeoJin Oh Republic of Korea
P-82 Optical Coherence Tomography Versus Visual Evoked Potentials in Optic Neuritis of Neuromyelitis Optica Spectrum Disorders Joong Yang Cho Republic of Korea
P-83 Bidirectional Degeneration in The Visual Pathway in Neuromyelitis Optica Spectrum Disorder (NMOSD) Decai Tian China
P-84 Clinical Characteristics and Outcomes of Connective Tissue Disease Accompanied Neuromyelitis Optica Spectrum Disease in Chinese Patients Yao Zhang China
P-85 Frequent Positivity of ANA and SSA during NMOSD Attacks in Patients without Co-existing SLE and Sjogren Syndrome: A Preliminary Observation Jyh Yung Hor Malaysia
P-86 Rheumatoid Factor May Associated with Disability in Neuromyelitis Optica Spectrum Disorder Hye Lim Lee Republic of Korea
P-87 Cerebrospilnal Fluid-Actin Related Protein 2/3 Complex Subunit 4 as an Astrocytic Foot Process Damage Marker of Aquaporin-4-Igg Positive Neuromyelitis Optica Spectrum Disorders Shuhei Nishiyama Japan
P-88 Serum IL-27, IL-23 and IL-35 Levels in Neuromyelitis Optica Spectrum Disorders with Aquaporin-4 and Multiple Sclerosis Egemen Idiman Turkey
P-89 Study of The Placentae of Patients with Neuromyelitis Optica Spectrum Disorder Yanyu Chang China
P-90 Association of Serum Cystatin C with Neuromyelitis Optica Yaqing Shu China
P-91 Neuroprotective Effect of Serum Creatinine in Korean Patients with Neuromyelitis Optica Spectrum Disorder Dong Sun Kim Republic of Korea
P-92 Hepatitis B Virus Infection in Patients with Neuromyelitis Optica Spectrum Disorder Yuge Wang China
P-93 Intestinal Microbiota Distinguish Neuromyelitis Optica Patients from Healthy Individuals in a Chinese Pilot Study Jun Li Gong China
P-94 Establishment and Management of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders (NMOSD) Nationwide Multicenter Registry in Korea Hye Lim Lee Republic of Korea
P-95 Usefulness of PLEX Treatment Using Peripheral Venous Access in Patients with NMO Sakamaki Masanori Japan
P-96 Evaluation of Classical Immunosuppressant Drugs-Cyclophosphamide, Methotrexate Among Patients with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Yuge Wang China
P-97 Bortezomib as Add-on Treatment for Highly Relapsing NMOSD Patients Chao Zhang China
P-98 CSF and MRI Findings of Acute Transverse Myelitis with Neuropathic Pain Jun Hong Lee Republic of Korea
P-99 Anti-neurofascin Antibodies in Patients with Acute Transverse Myelitis Combined with Peripheral Demyelination Li Yang China
P-100 Diurnal Pattern of Initial Attack in Patients with Early Onset of Optic Neuritis Mohammad Javad Eslami Iran
P-101 Severe Optic Neuritis: 72 Cases from Turkey Gulsen Akman-Demir Turkey
P-102 Intravenous Immunoglobulin Treatment for Recurrent Optic Neuritis Burcu Altunrende Turkey
P-103 Characteristics of Optic Neuropathy in Behcet’s Disease Gulsen Akman-Demir Turkey
P-104 Intracranial Hemorrhagic Lesion and Neurosarcoidosis Ryusei Nishigori Japan
P-105 Clinical Characteristics of Parenchymal Neuro-Behcet’s Disease in South Korea Seung Woo Kim Republic of Korea
P-106 Heterogeneity of Combined Central and Peripheral Demyelination: A Systematic Review Jong Seok Bae Republic of Korea
P-107 Oligodendroglia-Specific Connexin 47 Deletion Induced Relapse-Remitting EAE Model Mice Ryo Yamasaki Japan
P-108 The Antioxidant Properties and Anti-Inflammatory Effect of Sulforaphane in Mice with Experimental Autoimmune Encephalomyelitis Suk-Won Ahn Republic of Korea
P-109 Neutralization of the IL-19 Axis Diminishes Monocytes Invasion and Protects from Experimental Autoimmune Encephalomyelitis Xiaonan Zhong China
P-110 Autoreactive CD8+ Central Memory T Cells Failed to Induce Experimental Autoimmune Encephalomyelitis Guang-zhi Liu China
P-111 Fabry Disease or Multiple Sclerosis – Two Entities and Their Diagnostical and Treatment Challenges    Pavel Stourac Czech Republic
P-112 A Patient Diagnosed as Multiple Sclerosis with Severe Brain Atrophy Yool-hee Kim Republic of Korea
P-113 Diffuse Lesion in Limbic System with Short-term Memory Loss in a Patient with Multiple Sclerosis Yasuyuki Takai Japan
P-114 Epileptic Seizure as First Clinic Presentation of Multiple Sclerosis Şeref Demirkaya Turkey
P-115 Myelin Water Imaging in a Progressive Solitary Sclerosis Case Jillian Chan Canada
P-116 Condyloma Acuminata Aggravated in a Patient with Multiple Sclerosis after Fingolimod Therapy Mesrure Koseoglu Turkey
P-117 Induction Therapy with Cyclophosphamide and Rituximab followed by Fingolimod improves Outcomes in Fulminant Corticosteroid and Plasmapheresis Refractory Multiple Sclerosis Tee Sow Kuan Malaysia
P-118 Fingolimod-Associated PML with Mild Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis  Tatsuro Misu Japan
P-119 De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine) :3 Cases Mehmet Ozmenoglu Turkey
P-120 Hypothalamic Lesion Induced Symptomatic Narcolepsy in NMO Patient: A Case Report   Kartika Maharani Indonesia
P-121 Difficulty in Differential Diagnosis of Recurrent Brainstem Syndrome; Rhombencephalitis or Neuromyelitis optica? Sujin Lee Republic of Korea
P-122 Ectrodactyly in A Chinese Patient Born to A Mother with Neuromyelitis Optica Spectrum Disorder Yanyu Chang China
P-123 Neuromyelitis Optica Spectrum Disorder and Sjögren’s Syndrome: A Rare Clinical Phenotype Chen Fei Ng Malaysia
P-124 Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis Hung Youl Seok Republic of Korea
P-125 A Case Report of Behavioral Symptoms and Multiple Cranial Neuropathies in MOG-Igg Positive Patient Kyomin Choi Republic of Korea
P-126 Bıopsy Proven Aqp4-Ig G Seronegatıve Nmosd Case: Benıgn Course wıth No Treatment Ayse Altintas Turkey
P-127 B Cell Depleting Therapy for Multiple Sclerosis Overlapping with Neuromyelitis Optica Spectrum Disorder Tingting Lu China
P-128 Acute Disseminated Encephalomyelitis in Post-allogeneic Peripheral Blood Stem Cell Transplantation with Subclinical Cytomegalovirus Infection Chen Fei Ng Malaysia
P-129 Susac’s Syndrome in a Patient Misdiagnosed with Multiple Sclerosis: A Case Report Sze Chin Jong Singapore
P-130 Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases Mehmet Ozmenoglu Turkey
P-131 Recurrent Optic Neuritis in Patient with Behcet Disease Kyong Jin Shin Republic of Korea
P-132 Anti-LGI 1 Auto-Antibody Related Limbic Encephalitis: A Case Report Ufuk Emre Turkey
P-133 Area Postrema as The Initially Presenting Symptom of Primary Sjogren’s Syndrome  Yuge Wang China
P-134 Diffuse Leukoencephalopathy, a Rare Manifestation of Systemic Lupus Erythematosus Minsu Park Republic of Korea
P-135 Acute Toxic Hepatitis after Steroid Pulse Therapy in Myelopathy Jung Im Seok Republic of Korea
P-136 Optic Neuritis: A Complication of ZIKA Virus Infection in An Adult Sze Tung Lam Singapore
P-137 Progressive Multifocal Leukoencephalopathy after Liver Transplantation Yool-hee Kim Republic of Korea
P-138 Central Pontine Myelinolysis without Rapid Correction of Hyperosmolar Hyperglycemia Jae Young An Republic of Korea